Impaired balance - Nyxol meets endpoint in phase 3 night vision disturbance trial

Nyxol demonstrated positive topline results in subjects with night vision disturbances in the phase 3 LYNX-1 pivotal clinical trial, Ocuphire Pharma announced in a press...